News & Updates
Filter by Specialty:
Ivarmacitinib efficacious, well tolerated in moderate-to-severe alopecia areata
Use of ivarmacitinib 4- and 8-mg doses for 24 weeks eases hair loss and is generally tolerated in patients with moderate or severe alopecia areata (AA), a phase II study has shown.
Ivarmacitinib efficacious, well tolerated in moderate-to-severe alopecia areata
27 Oct 2023
One BPG dose may be enough to treat syphilis, regardless of HIV status
Three doses of benzathine penicillin G (BPG) are not necessarily better than a single dose in the treatment of early syphilis in individuals with or without HIV infection, as shown in a study.
One BPG dose may be enough to treat syphilis, regardless of HIV status
26 Oct 2023
Niraparib tied to more toxicities than olaparib in ovarian cancer
Use of niraparib appears to contribute to a higher risk of haematological toxicities as compared with olaparib, suggests a study. The most common haematological adverse event is anaemia.
Niraparib tied to more toxicities than olaparib in ovarian cancer
25 Oct 2023
Pooled EAGLE subgroup analyses boost gepotidacin potential for uUTI in females
In a pooled analyses of data from the EAGLE*-2 and EAGLE-3 studies, the investigational, first-in-class, oral, triazaacenaphthylene bactericidal antibiotic gepotidacin showed consistent therapeutic efficacy across key patient subgroups and had an acceptable safety profile in female adults and adolescents with uncomplicated urinary tract infections (uUTI) compared with nitrofurantoin.